Brief Summary
The purpose of the study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of AZD2962, an Interleukin-1 Receptor-Associated Kinase 4 (IRAK4) inhibitor, as monotherapy and in combination with other agents in participants with haematologic neoplasms.
Intervention / Treatment
- Drug: AZD2962
Inclusion Criteria
- Participants with relapsed/refractory MDS or participants with relapsed/refractory dysplastic CMML, with peripheral blasts or bone marrowsoft, spongy tissue found in bones that makes blood cells blasts < 20%, and who received one or more prior lines of therapy as per standard of care (or who exhausted locally available treatments including treatments for actionable mutations). Diagnosisthe process of identifying a disease based on signs and symptoms, patient history and medical test results must be histologically confirmed as per the WHO 2016 classification of myeloid neoplasms.
- Eastern Cooperative Oncologythe study, diagnosis and treatment of cancer Group (ECOG) performance status of ≤2.
- Participants must have symptomatic disease that requires therapy and allows for objective efficacy assessments.
- Willing to provide baseline bone marrow aspirateto draw out fluid or tissue from the body, often with a syringe (or biopsyremoval of a section of tissue to analyse for cancer cells if dry-tap).
- Contraceptive use by participants or participant partners should be consistent with local regulations and also comply with Clinical Study Protocol requirements.
- All women of childbearing potential must have a negative serum pregnancy test result at Screeningtesting for cancer or conditions that can lead to cancer before symptoms appear, also known as cancer screening.